TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).
Hemogenyx Pharmaceuticals has raised £451,250 to continue its Phase 1 clinical trials for its Chimeric Antigen Receptor T-cell therapy, HG-CT-1, targeting relapsed/refractory acute myeloid leukemia in adults. This funding, secured at a premium, reflects investor confidence in the company’s long-term potential and allows the advancement of their pivotal therapy without significant dilution, potentially strengthening their position in the biopharmaceutical industry.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company based in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging platform technologies for novel product development.
Average Trading Volume: 40,185
Technical Sentiment Signal: Sell
Current Market Cap: £7.59M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.